Xenetic Biosciences PLC Director Dealings (0053X)

TIDMXEN

RNS Number : 0053X

Xenetic Biosciences PLC

06 January 2014

6 January 2014

Xenetic Biosciences plc ("Xenetic" or the "Company")

Directors Dealings

Xenetic Bio (AIM: XEN.L), a bio-pharmaceutical company specialising in the development of high-value differentiated biologics, vaccines and novel cancer drugs, was informed on 23 December 2013 of the following dealings by Directors and their connected persons ("Dealings"). The dealings took place on 20 December 2013, at a price of 4.5 pence per ordinary shares of 0.5 pence each ("Ordinary Shares") in the Company.

 
 Director         Beneficial      % of share   Shares      Beneficial      % beneficial 
                   holding         capital      acquired    holding         holding 
                   of Ordinary     prior                    of Ordinary     of Ordinary 
                   Shares          to the                   Shares          Shares 
                   prior to        Dealings                 following       following 
                   the Dealings                             the Dealings    the Dealings 
---------------  --------------  -----------  ----------  --------------  -------------- 
 Scott Maguire    1,401,361       0.34         25,000      1,426,361       0.35 
---------------  --------------  -----------  ----------  --------------  -------------- 
 Colin Hill       1,825,420       0.45         50,000      1,875,420       0.46 
---------------  --------------  -----------  ----------  --------------  --------------

The Company's issued share capital consists of 408,048,487 Ordinary Shares with voting rights. The Company does not hold any Ordinary shares in treasury.

Enquiries:

 
Xenetic Biosciences plc                          www.xeneticbio.com 
M. Scott Maguire, Chief Executive 
 Officer                                        +44 (0)20 3021 1500 
Colin Hill, Chief Financial Officer 
London Bridge Capital (Financial 
 Adviser to Xenetic)                             +44 (0)7912 201639 
Adam Hart 
 
N+1 Singer (Nominated Adviser & 
 Broker)                                        +44 (0)20 7496 3000 
Aubrey Powell 
 
Walbrook PR                                     +44 (0)20 7933 8780 
Mike Wort (Media Enquiries)                mike.wort@walbrookpr.com 
Paul Cornelius (Investor Enquiries)   paul.cornelius@walbrookir.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSBUGDBSBGBGSL

Xenetic Bio (LSE:XEN)
過去株価チャート
から 5 2024 まで 6 2024